GHAPPcast: The Clinical Utility of Guselkumab in CD

Thank you to Johnson & Johnson for your support of this GHAPPcast episode.Join host Gabriella McCarty, NP-C, and special guest Teddy Solomon, NP, from Cedars-Sinai, for an in-depth discussion on The Clinical Utility of Guselkumab in Crohn’s Disease. In this episode of GHAPPcast—the official podcast of the Gastroenterology & Hepatology Advanced Practice Providers (GHAPP)—we examine how this IL-23 inhibitor may fit into the evolving treatment landscape for patients with Crohn’s disease.Teddy, a recognized IBD expert and plenary speaker at the recent GHAPP National Conference, shares clinical insights, trial data, and personal perspectives on the unique mechanism of action behind guselkumab. You’ll learn about its potential role in induction and maintenance therapy, the results of the GRAVITI and GALAXI trials, and how it compares to other therapies like ustekinumab and risankizumab. We also explore which patient profiles may benefit most from guselkumab and which scenarios may call for a different approach.Whether you're biologic-naive or exploring options beyond TNF inhibitors, this episode will give you tools to navigate shared decision-making and better support patients through personalized IBD care.Subscribe to GHAPPcast on your favorite podcast platform, and visit ghapp.org for more expert-led resources and clinical tools for APPs in GI and hepatology.